- Home
- FGNX vs ICCC Comparison
FGNX vs ICCC Comparison
Compare FGNX & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FGNX | ICCC |
|---|---|---|
| Founded | 1932 | 1982 |
| Country | United States | United States |
| Employees | 130 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 55.5M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | FGNX | ICCC |
|---|---|---|
| Price | $5.03 | $6.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $36.50 | N/A |
| AVG Volume (30 Days) | ★ 62.6K | 12.2K |
| Earning Date | 05-19-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.33 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | $95.83 | N/A |
| Revenue Next Year | $42.41 | N/A |
| P/E Ratio | ★ N/A | $32.60 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $1.59 | $4.52 |
| 52 Week High | $18.42 | $7.60 |
Technical Indicators
Market Signals| Indicator | FGNX | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 36.85 | 46.52 |
| Support Level | $2.48 | $6.20 |
| Resistance Level | $6.36 | $6.79 |
| Average True Range (ATR) | 0.43 | 0.18 |
| MACD | -0.32 | 0.01 |
| Stochastic Oscillator | 1.09 | 39.26 |
Price Performance
Historical ComparisonAbout FGNX Fundamental Global Inc.
FG Nexus Inc is a capital markets platform focused on long-term Ethereum (ETH) accumulation and on-chain yield generation. The company provides institutional investors with secure, regulated access to ETH as a productive reserve asset, generating native staking yield while underpinning stablecoins, tokenized assets, and AI-driven applications.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.